(Q38978347)

8 September 2017

1 reference

title

NAFLD and diabetes mellitus (English)

1 reference

8 September 2017

Herbert Tilg

1

1 reference

8 September 2017

Alexander R Moschen

series ordinal

2

1 reference

8 September 2017

Michael Roden

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

12 October 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

8 September 2017

1 reference

8 September 2017

14

1 reference

8 September 2017

1

1 reference

8 September 2017

32-42

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2016.147

8 September 2017

0 references

cites work

Current efforts and trends in the treatment of NASH

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Noninvasive evaluation of NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A population-based study on the prevalence of NASH using scores validated against liver histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Pathological features of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Non-alcoholic steatohepatitis: a microbiota-driven disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Defective liver disposal of free fatty acids in patients with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Splanchnic lipolysis in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Lipid overload and overflow: metabolic trauma and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Lower fasting muscle mitochondrial activity relates to hepatic steatosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Abnormal hepatic energy homeostasis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mitochondria and redox signaling in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Inflammatory mechanisms in the regulation of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The origins and drivers of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Metabolic syndrome: a clinical and molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Different frequencies of angiotensin-converting enzyme genotypes in older hypertensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Mechanisms for insulin resistance: common threads and missing links

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Inflammation, cytokines and insulin resistance: a clinical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Cytokines in alcoholic and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

IKK-beta links inflammation to obesity-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Endocrine regulation of energy metabolism by the skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Immunological goings-on in visceral adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Gamma-glutamyltransferase and diabetes--a 4 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Extrahepatic complications of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Resolution of fatty liver and risk of incident diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

NAFLD: a multisystem disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

[Fatty liver, its causes and concomitant diseases.]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.147

Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27729660

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27729660

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2016.147

1 reference

8 September 2017

1 reference